<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922870</url>
  </required_header>
  <id_info>
    <org_study_id>1450</org_study_id>
    <nct_id>NCT00922870</nct_id>
  </id_info>
  <brief_title>Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock</brief_title>
  <acronym>Cascade</acronym>
  <official_title>Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gambro Lundia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is a major cause of mortality and morbidity in critically ill patients. Septic&#xD;
      Shock is associated with an overwhelming, systemic overflow of pro inflammatory and&#xD;
      anti-inflammatory mediators, which leads to generalized endothelial damage, multiple organ&#xD;
      failure, and altered cellular immunological responsiveness. Although our understanding of the&#xD;
      complex pathophysiological alterations that occur in septic shock has increased greatly as a&#xD;
      result of recent clinical and preclinical studies, mortality associated with the disorder&#xD;
      remains unacceptably high, ranging from 30% to 50%. To date, attempts to improve survival&#xD;
      with innovative, predominantly anti-inflammatory therapeutic strategies have been&#xD;
      disappointing. A standard hemofiltration rate of 35 ml/kg/hour has been successfully used to&#xD;
      treat acute renal failure. However, this dose does not alter plasma levels of inflammatory&#xD;
      mediators, suggesting that its ability to clear these mediators is suboptimal. Higher doses&#xD;
      of hemofiltration (up to 120 ml/kg per hour) have been demonstrated to improve cardiac&#xD;
      function and hemodynamics in several animal models of sepsis. High-volume hemofiltration&#xD;
      (HVHF) was thus conceived and applied in patients with septic shock, showing an improvements&#xD;
      in hemodynamics with decreased vasopressor requirements and improved survival in patients&#xD;
      admitted after a cardiac arrest.&#xD;
&#xD;
      The main benefit described with high volume hemofiltration is a hemodynamic improvement (e.g&#xD;
      reduction in catecholamines' requirement). This improvement seems to be due to the removal of&#xD;
      a badly defined network of middle molecular weight peptides. To remove efficiently these&#xD;
      middle molecular peptides, a high filtration rate is needed. However, with high filtration&#xD;
      rates, there is also a high clearance for smaller molecules, including antibiotics,&#xD;
      electrolytes, vitamins, trace elements and amino acids.&#xD;
&#xD;
      The cascade hemofiltration system has been designed for a more efficient removal of middle&#xD;
      molecular weight peptides with a limited solute consumption.&#xD;
&#xD;
      The goal of this study is the evaluation of the hemodynamic improvement using cascade&#xD;
      hemofiltration in patients treated for septic shock.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the primary outcome will be the number of days without catecholamines at the 28th day of randomization</measure>
    <time_frame>28th day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of decrease of catecholamines during the first 72h, days without mechanical ventilation at D90, days without RRT for acute renal failure at D90, days without ICU requirement at D90, status at D90.</measure>
    <time_frame>72h, D90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cascade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cascade</intervention_name>
    <description>Cascade treatment over 48h</description>
    <arm_group_label>Cascade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Standard therapy</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with a septic shock diagnosed by the medical staff team.&#xD;
&#xD;
          -  Patient mechanically ventilated and treated by high doses of catecholamines after&#xD;
             adequate fluid administration (≥ 1.0 mg/h of norepinephrine or epinephrine) for ≥ 120&#xD;
             minutes and &lt; 24h.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age (years) &lt; 18 or &gt; 85.&#xD;
&#xD;
          -  Weight &gt;120 kg&#xD;
&#xD;
          -  Thrombocytopenia 50&lt; G/l or Neutrophils &lt;0.5 Giga/l&#xD;
&#xD;
          -  Contra indication to heparin anticoagulation.&#xD;
&#xD;
          -  Patient requiring catecholamines (epinephrine ≥ 1 mg/h or norepinephrine ≥ 1 mg/h) for&#xD;
             &gt;24h.&#xD;
&#xD;
          -  Patient admitted to the ICU ≥ 7 days before the inclusion criteria.&#xD;
&#xD;
          -  Comorbid conditions with an expected survival &lt; 6 months&#xD;
&#xD;
          -  Inclusion (&lt;28 days) in another study interfering with the goals of the current&#xD;
             investigation.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Immune compromised patients (e.g. being treated for cancer, treated by&#xD;
             immunosuppressors or steroids, AIDS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monchi Mehran, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Unaffiliate</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Marc JACQUET</name>
      <address>
        <city>Melun</city>
        <zip>77 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Delafontaine</name>
      <address>
        <city>Saint Denis</city>
        <zip>93205</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

